Dagmar von Bubnoff1, Marina Scheler2, Helene Wilms2, Jörg Wenzel2, Nikolas von Bubnoff3, Georg Häcker4, Joachim Schultze5, Alexey Popov5, Paul Racz6, Thomas Bieber2, Claudia Wickenhauser7. 1. Department of Dermatology, Friedrich-Wilhelms-University, Bonn, Germany. Electronic address: d.bubnoff@uni-bonn.de. 2. Department of Dermatology, Friedrich-Wilhelms-University, Bonn, Germany. 3. III Medizinische Klinik, Klinikum Rechts der Isar, Technische Universität München, München, Germany. 4. Institute of Medical Microbiology and Hygiene, University of Freiburg, Freiburg, Germany. 5. Institute for Life and Medical Sciences Bonn, Friedrich-Wilhelms-University, Bonn, Germany. 6. Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany. 7. Institute of Pathology, University of Leipzig, Leipzig, Germany.
Abstract
BACKGROUND: The enzyme indoleamine 2,3-dioxygenase (IDO) degrades the essential amino acid tryptophan, and this degradation is an immunosuppressive mechanism that is mainly used by antigen-presenting cells. IDO-expressing dendritic cells and macrophages have previously been identified as components of lymph node granulomas after Listeria monocytogenes infection. In this study we undertook an analysis of IDO expression in granulomas of infectious and noninfectious origin in the human skin. METHODS: Lesional skin biopsy specimens (n = 22) from different granulomatous skin disorders (lupus vulgaris, sarcoidosis, granuloma annulare, leprosy) were analyzed. Immunohistochemistry was performed to identify and locate the enzyme IDO within the inflammatory granulomatous infiltrate (IDO, CD11c, CD68, S100, CD3, Foxp3). Two-color immunofluorescence of IDO in combination with multiple markers was applied to characterize the IDO-expressing cells. RESULTS: Cutaneous granulomas of different origin strongly express IDO, mainly in the center and in the ring wall of the granulomas. We demonstrate that in infectious, but also in noninfectious human cutaneous granulomas the large myeloid CD11c(+)S100(+)CD68(-) dendritic cells and the CD68(+) macrophages express IDO. LIMITATIONS: This study was limited by the lack of details about the exact stage or maturity of granuloma formation in the specimens investigated. CONCLUSION: These findings reveal that IDO expression in myeloid dendritic cells and macrophages is part of an integrated response of granuloma formation, which may be a unifying feature of granulomatous reactions in the skin.
BACKGROUND: The enzyme indoleamine 2,3-dioxygenase (IDO) degrades the essential amino acid tryptophan, and this degradation is an immunosuppressive mechanism that is mainly used by antigen-presenting cells. IDO-expressing dendritic cells and macrophages have previously been identified as components of lymph node granulomas after Listeria monocytogenes infection. In this study we undertook an analysis of IDO expression in granulomas of infectious and noninfectious origin in the human skin. METHODS: Lesional skin biopsy specimens (n = 22) from different granulomatous skin disorders (lupus vulgaris, sarcoidosis, granuloma annulare, leprosy) were analyzed. Immunohistochemistry was performed to identify and locate the enzyme IDO within the inflammatory granulomatous infiltrate (IDO, CD11c, CD68, S100, CD3, Foxp3). Two-color immunofluorescence of IDO in combination with multiple markers was applied to characterize the IDO-expressing cells. RESULTS:Cutaneous granulomas of different origin strongly express IDO, mainly in the center and in the ring wall of the granulomas. We demonstrate that in infectious, but also in noninfectious humancutaneous granulomas the large myeloid CD11c(+)S100(+)CD68(-) dendritic cells and the CD68(+) macrophages express IDO. LIMITATIONS: This study was limited by the lack of details about the exact stage or maturity of granuloma formation in the specimens investigated. CONCLUSION: These findings reveal that IDO expression in myeloid dendritic cells and macrophages is part of an integrated response of granuloma formation, which may be a unifying feature of granulomatous reactions in the skin.
Authors: Tracy L Keller; Davide Zocco; Mark S Sundrud; Margaret Hendrick; Maja Edenius; Jinah Yum; Yeon-Jin Kim; Hak-Kyo Lee; Joseph F Cortese; Dyann F Wirth; John David Dignam; Anjana Rao; Chang-Yeol Yeo; Ralph Mazitschek; Malcolm Whitman Journal: Nat Chem Biol Date: 2012-02-12 Impact factor: 15.040
Authors: Michelle A Krupna-Gaylord; Dionysios Liveris; Andrea C Love; Gary P Wormser; Ira Schwartz; Mary M Petzke Journal: PLoS One Date: 2014-06-19 Impact factor: 3.240
Authors: Roberta Olmo Pinheiro; Veronica Schmitz; Bruno Jorge de Andrade Silva; André Alves Dias; Beatriz Junqueira de Souza; Mayara Garcia de Mattos Barbosa; Danuza de Almeida Esquenazi; Maria Cristina Vidal Pessolani; Euzenir Nunes Sarno Journal: Front Immunol Date: 2018-03-28 Impact factor: 7.561